Back to top
more

Vascular Biogenics Ltd. (VBLT)

(Delayed Data from NSDQ)

$1.28 USD

1.28
10,710

+0.01 (0.79%)

Updated May 3, 2019 03:59 PM ET

After-Market: $1.28 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -9.09% and 220.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Biofrontera Inc. (BFRI) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 28.13% and 0.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 10.89% and 60.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Dynavax Technologies (DVAX) Beats Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Dynavax Technologies (DVAX) delivered earnings and revenue surprises of 30.30% and 11.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07

by Zacks Equity Research

Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.

Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose

by Zacks Equity Research

Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.

Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product

by Zacks Equity Research

Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.

Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 17.33% and 121.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Vascular Biogenics (VBLT) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Vascular Biogenics (VBLT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 26.39% and 9.83%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails

by Zacks Equity Research

Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.

    Vascular Biogenics (VBLT) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -8.33% and 42.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Kala Pharmaceuticals (KALA) Reports Q1 Loss, Misses Revenue Estimates

    by Zacks Equity Research

    Kala Pharma (KALA) delivered earnings and revenue surprises of -25% and 55.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    ITeos Therapeutics, Inc. (ITOS) Surpasses Q1 Earnings and Revenue Estimates

    by Zacks Equity Research

    iTeos Therapeutics, Inc. (ITOS) delivered earnings and revenue surprises of 127.50% and 140.95%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

    by Zacks Equity Research

    Editas (EDIT) delivered earnings and revenue surprises of 8.64% and 44.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Harmony Biosciences Holdings, Inc. (HRMY) Beats Q1 Earnings Estimates

    by Zacks Equity Research

    Harmony Biosciences Holdings, Inc. (HRMY) delivered earnings and revenue surprises of 104% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

    Fulcrum Therapeutics, Inc. (FULC) Stock Jumps 5.7%: Will It Continue to Soar?

    by Zacks Equity Research

    Fulcrum Therapeutics, Inc. (FULC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

    Vascular Biogenics (VBLT) Reports Q4 Loss, Lags Revenue Estimates

    by Zacks Equity Research

    Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -50% and 2%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Regenxbio (RGNX) Q4 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    Regenxbio (RGNX) delivered earnings and revenue surprises of 55.84% and 29.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure

    by Zacks Equity Research

    BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend. The study continues.

    Reata (RETA) Falls on Negative Advisory Committee Outcome

    by Zacks Equity Research

    An FDA advisory committee believes Reata's (RETA) bardoxolone study data does not support the effectiveness of the candidate in slowing the progression of CKD in patients with Alport syndrome.